RGEN (Repligen) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


RGEN Repligen Corp RGEN
83 GF Score
Price $138.47
GF Value $175.89
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Repligen Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Repligen's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

RGEN vs ATR, AVTR, TFX: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Repligen Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Repligen's Margin of Safety % (DCF FCF Based) falls into.


RGEN
83GF Score
Repligen Corp RGEN
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Repligen (RGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of $138.47 is trading 21.3% below its estimated GF Value™ of $175.89. GuruFocus considers Repligen to be Modestly Undervalued.

Key valuation signals for RGEN:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $175.89 vs. price of $138.47 (21.3% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Repligen Business Description

Other Exchanges RGN:Germany
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score

Get the complete analysis for RGEN

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$138.47
Price
$175.89
GF Value